Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome
Kuculmez O. Frontiers in Medicine, 2026.
- Study type
- Cohort study
- People studied
- 40 people
- Population
- Patients diagnosed with post-COVID syndrome
- Published
- 2026, Frontiers in Medicine
- Identifiers
- PMID 41767530, DOI 10.3389/fmed.2026.1720578
What the authors reported
A retrospective review of 40 patients given 10 sessions of major ozone autohemotherapy for post-COVID syndrome found statistically significant improvement in anxiety, depression, fatigue, and quality-of-life scores after treatment.
What limits this result
Retrospective single-center chart review with no control group and no blinding; a before-after comparison cannot rule out natural recovery or other concurrent care.
Other ozone methods, such as major autohemotherapy, that clinics cite in support of EBO2. A result for one method does not transfer automatically to another. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) for Long COVID: What Has Been Studied
What NIH RECOVER, FDA enforcement action, and small ozone autohemotherapy trials actually show about EBO2 (also called EBOO) and long COVID symptoms.